Endocrinology Journal Article

Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures

July 19, 2019

Maria Fankhauser, Nicole Bechmann, Michael Lauseker, Judith Goncalves, Judith Favier, Barbara Klink, Doreen William, Laura Gieldon, Julian Maurer, Gerald Spöttl, Petra Rank, Thomas Knösel, Michael Orth, Christian G Ziegler, Elke Tatjana Aristizabal Prada, German Rubinstein, Martin Fassnacht, Christine Spitzweg, Ashley B Grossman, Karel Pacak, Felix Beuschlein, Stefan R Bornstein, Graeme Eisenhofer, Christoph J Auernhammer, Martin Reincke, Svenja Nölting
Endocrinology, Volume 160, Issue 11, November 2019, Pages 2600–2617
https://doi.org/10.1210/en.2019-00410

Abstract

There are no officially approved therapies for metastatic pheochromocytomas apart from ultratrace 131I-metaiodbenzylguanidine therapy, which is approved only in the United States. We have, therefore, investigated the antitumor potential of molecular-targeted approaches in murine pheochromocytoma cell lines [monocyte chemoattractant protein (MPC)/monocyte chemoattractant protein/3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)], immortalized mouse chromaffin Sdhb−/− cells, three-dimensional pheochromocytoma tumor models (MPC/MTT spheroids), and human pheochromocytoma primary cultures. We identified the specific phosphatidylinositol-3-kinase α inhibitor BYL719 and the mammalian target of rapamycin inhibitor everolimus as the most effective combination in all models. Single treatment with clinically relevant doses of BYL719 and everolimus significantly decreased MPC/MTT and Sdhb−/− cell viability. A targeted combination of both inhibitors synergistically reduced MPC and Sdhb−/− cell viability and showed an additive effect on MTT cells. In MPC/MTT spheroids, treatment with clinically relevant doses of BYL719 alone or in combination with everolimus was highly effective, leading to a significant shrinkage or even a complete collapse of the spheroids. We confirmed the synergism of clinically relevant doses of BYL719 plus everolimus in human pheochromocytoma primary cultures of individual patient tumors with BYL719 attenuating everolimus-induced AKT activation. We have thus established a method to assess molecular-targeted therapies in human pheochromocytoma cultures and identified a highly effective combination therapy. Our data pave the way to customized combination therapy to target individual patient tumors.

Read the article


You may also like...

Endocrinology

Search underway for the next Editor-in-Chief

The Endocrine Society seeks the next Editor-in-Chief (EIC) of Endocrinology, the Society’s premier basic science journal, publishing continuously online on basic and translational research at molecular, biochemical, cellular, genomic, comparative, and organismal levels.

The Endocrine Society seeks the next Editor-in-Chief (EIC) of Endocrinology, the Society’s premier basic science journal, publishing continuously online on basic and translational research at molecular, biochemical, cellular, genomic, comparative, and organismal levels.

Thematic Issue

Immuno-endocrinology 2020

immuno-endocrinology
Read our special collection of journal articles, published in 2018-2019, focused on immuno-endocrinology! Curation of the collection was guided by Altmetric Attention Scores and Featured Article designations.

Read our special collection of journal articles, published in 2018-2019, focused on immuno-endocrinology! Curation of the collection was guided by Altmetric Attention Scores and Featured Article designations.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!